



04-22-04

sfw
1624
27

Docket No. ORT1478

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: J. Guy BREITENBUCHER et al.

Serial No.: 09/928,122

Filed : August 10, 2001

Examiner: EMILY B. BERNHARDT

For : SUBSTITUTED PYRAZOLES

Art Unit: 1624

I hereby certify that this correspondence is being deposited with the
United States Postal Service as Express Mail No. EU642140963US. in an envelope addressed
to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

September 21, 2004
(Date of Deposit)

Jesús Juanós i Timoneda
(Name of applicant, assignee, or Registered Representative)

[Signature]
(Signature)

September 21, 2004
(Date of Signature)

Commissioner for Patents.
P.O. Box 1450
Alexandria, VA 22313-1450

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the Information Disclosure Statement mailed on September 27, 2002.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☐ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☒ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with §1.97(e) (attached); or

☒ Please charge Deposit Account No. 10-0750/ORT1478/JJiT the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☐ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2). (The U.S. patents and each U.S. patent application publication listed on the attached Form PTO-1449 are not enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i)).

☒ There are no listed references which are not in the English language, except for where English language Abstracts are provided for all those references in foreign languages.

☐ The relevance of those listed references which are not in the English language is as follows:


☐ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

Copies of the references listed on the search report(s) are included except for those previously cited in an IDS mailed .

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/ORT1478/JJiT. This form is submitted in triplicate.


Respectfully submitted,



Jesús Juanós i Timoneda
Reg. No. 43,332
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-1513

DATED: *September 21, 2004*



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	09/928,122
Filing Date	08/10/2001
First Named Inventor	J. Guy BREITENBUCHER
Group Art Unit	1624
Examiner Name	EMILY B. BERNHARDT
Attorney Docket Number	ORT 1478

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Translation	T ²
		CHAPMAN, H.A. et al., "Emerging Roles for Cysteine Proteases in Human Biology"; Annu. Rev. Physiol. (1997) 59:63-88.	No	
		CHAPMAN, H.A. et al., "Endosomal Proteolysis and MHC Class II Function"; Curr. Opin. in Immunol. (1998) 10:93-102.	No	
		GAGA, et al., "Eosinophil Activation and T Lymphocyte Infiltration in Allergen-Induced Late Phase Skin Reactions and Classical Delayed-Type Hypersensitivity" Journal. Immun. (1991) 147:816-822.	No	
		MAURER, D. et al., "Fce Receptor I on Dendritic Cells Delivers IgE-Bound Multivalent Antigens into a Cathepsin S-Dependent Pathway of MHC Class II Presentation" J. Immunol. (1998) 161:2731-2739.	No	
		NAKAGAWA, T.Y. et al., "Impaired Invariant Chain Degradation and Antigen Presentation and Diminished Collagen-Induced Arthritis in Cathepsin S Null Mice"; Immunity (1999) 10:207-217	No	
		NAKAGAWA, T.Y. et al., "The role of lysosomal proteinases in MHC class II-mediated antigen processing and presentation" Immunological Rev. (1999) 172:121-129.	No	
		PALUCHOWSKA, et al., Polish J. Pharmacology 51(5), 415-421 (1999) "Structure-Activity Relationship Studies of CNS Agents part 40. "EFFECT OF THE AMIDE FRAGMENT ON 5-HT _{1A} RECEPTOR ACTIVITY OF SOME ANALOGS OF MP 3022"	No	
		PALUCHOWSKA, et al., Polish J. Pharmacology 52(3), 209-216 (2000) "INFLUENCE OF THE ALIPHATIC SPACER LENGTH ON THE 5-HT _{1A} RECEPTOR ACTIVITY OF NEW ARYLPIPERAZINES WITH AN INDAZOLE SYSTEM"	No	
		RIESE, R.J. et al., "Cathepsin S Activity Regulates Antigen Presentation and Immunity"; J. Clin Invest. (1998) 101 (11):2351-2363.	No	
		RIESE, R.J. et al., "Cathepsins and Compartmentalization in Antigen Presentation; Curr. Opin. Immunol. (2000) 12:107-113	No	
		RIESE, R.J. et al., "Essential Role for Cathepsin S in MHC Class II-Associated Invariant Chain Processing and Peptide Loading: Immunity (1996) 4:357-366.	No	
		VILLADANGOS, J.A. et al., "Degradation of Mouse Invariant Chain: Roles of Cathepsins S and D and the Influence of Major Histocompatibility Complex Polymorphism" J. Exp. Med. (1997) 186(4):549-560.	No	
		VILLADANGOS, J.A. et al., "Proteases Involved in MHC Class II Antigen Presentation" Immunological Rev. (1999) 172:109-120.	No	
		VILLADANGOS, J.A. et al., "Proteolysis in MHC Class II Antigen Presentation: Who's in Charge?"; Immunity (2000) 12:233-239.	No	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.